Dr. Emmanuel S. Antonarakis on the Future of the AR-V7 Biomarker in Prostate Cancer
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, on the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker.
Emmanuel S. Antonarakis, MBBCh, associate professor, Johns Hopkins Medicine, discusses the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker. Antonarakis says in the future, the ARV7 marker could be an indicator for certain treatments like an androgen receptor therapy, such as enzalutamide or abiraterone, or a chemotherapy like docetaxel or cabazitaxel.
Antonarakis adds that it is only a matter of time before phase II and phase III trials will be available for oncologists to put patients on, specifically patients who express ARV7.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
